Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies

OBJECTIVE: This study aimed to evaluate the long-term safety and efficacy of olokizumab (OKZ), an anti-interleukin (IL)-6 monoclonal antibody, in patients with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor-alpha inhibitors. METHODS: Eligible patients completed study RA00...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., Durez, Patrick, Fleischmann, Roy, Tanaka, Yoshiya, Furst, Daniel, Yamanaka, Hisashi, Korneva, Elena, Vasyutin, Igor, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770405/
https://www.ncbi.nlm.nih.gov/pubmed/34101570
http://dx.doi.org/10.5152/eurjrheum.2021.19207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770405/
https://www.ncbi.nlm.nih.gov/pubmed/34101570
http://dx.doi.org/10.5152/eurjrheum.2021.19207

Ejemplares similares